The Emcure Pharma IPO commenced on July 3, 2024, and concluded on July 5, 2024. The allotment of shares took place on July 8, 2024, and the initiation of refunds began on July 9, 2024. The shares were credited to the demat accounts of investors on July 9, 2024. Finally, the listing of Emcure Pharma on the stock exchange occurred on July 10, 2024.
The Emcure Pharma IPO was priced at ₹960 to ₹1008 per share, with a lot size of 14 shares. The total size of Emcure Pharmaceuticals IPO is ₹1,952.03 crores out of which ₹800.00 crores is fresh issue and ₹1,152.03 crores is offer for sale (OFS). The IPO was listed on both the NSE and BSE.
In terms of quota reservations, the QIB (Qualified Institutional Buyers) quota was reserved for 50% of the shares, the NII (Non-Institutional Investors) quota was reserved for 15% of the shares, and the retail quota was reserved for 35% of the shares.
Emcure Pharma IPO Basic Details
| Company Name | Emcure Pharmaceuticals Limited |
| Domain of Company | Pharma Company |
| Aasaan Loans IPO GMP Today | ₹290 |
| Aasaan Loans IPO Listing Gain | 28.77% |
| Aasaan Loans IPO Open Date | July 3, 2024 |
| Aasaan Loans IPO Close Date | July 5, 2024 |
| Aasaan Loans IPO Allotment Date | July 8, 2024 |
| Aasaan Loans IPO Listing Date | July 10, 2024 |
| Face Value | ₹10 per share |
| Price | ₹960 to ₹1008 per share |
| Lot Size | 14 Shares |
| Issue Size | 9,365,346 shares of ₹10 (aggregating up to ₹1,952.03 Cr) |
| Fresh Issue | 7,936,507 shares of ₹10 (aggregating up to ₹800.00 Cr) |
| Offer for Sale | 11,428,839 shares of ₹10 (aggregating up to ₹1,152.03 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE, BSE |
| Company Promoters | Satish Mehta and Sunil Mehta |
Emcure Pharma IPO GMP Today:
| Date | GMP | Listing Gain | Kostak | Subject to |
| Today | ₹290 | 28.77% | – | – |
| 1 July 2024 | ₹290 | 28.77% | – | – |
Emcure Pharmaceuticals IPO Details:
Emcure Pharmaceuticals Limited, founded in 1981, is an Indian company that develops, manufactures, and sells a wide range of pharmaceutical products worldwide.
Market Position and Therapeutic Leadership
As of September 2023, Emcure ranks 13th in domestic sales among Indian pharmaceutical companies and holds the 4th largest market share in its covered markets. Notably, Emcure is a leader in the gynaecology and HIV antiviral therapeutic areas.
Financial Performance
In the first half of 2023 and throughout the Financial Year 2023, Emcure’s sales in India accounted for 50.84% and 53.16% of its total revenue, respectively. The company’s domestic sales grew at an impressive CAGR of 10.80% from September 2019 to September 2023, surpassing the overall growth of the Indian pharmaceutical market.
Research and Development
By September 30, 2023, Emcure employed 552 scientists and operated five research facilities in India. The company has filed over 1,800 documents globally, including 204 in the EU and 133 in Canada. Emcure holds 201 granted patents, has 33 pending patent applications, and has submitted 102 drug master files.
Manufacturing Capabilities
Emcure operates 13 manufacturing facilities in India, producing a variety of pharmaceutical and biopharmaceutical products such as pills, liquids, injectables, and complex ingredients like chiral molecules, iron molecules, and cytotoxic substances.
Marketing and Distribution Network
As of September 30, 2023, Emcure’s extensive marketing and distribution network in India includes over 5,000 field personnel and more than 5,000 stockists, supported by 37 carry-and-forward agents, ensuring regular interaction with healthcare providers and effective distribution of their products.
Emcure Pharma IPO More Details Click Here
Emcure Pharma IPO FAQs
When is Emcure Pharma IPO open?
Emcure Pharma IPO will open on 3 July 2024.
When is Emcure Pharma IPO Close?
Emcure Pharma IPO will be closed on 5 July 2024.
What is Emcure Pharma IPO GMP Today?
The Emcure Pharma IPO GMP aka Grey Market Premium is ₹290.
What is Emcure Pharma IPO Kostak Rates Today?
The Emcure Pharma IPO Kostak Rate is ₹000.
What is Emcure Pharma IPO Subject to Sauda Price Today?
The Emcure Pharma IPO subject to sauda rates is ₹000.
Emcure Pharma IPO Expected Returns?
The Emcure Pharma expected return is 28.77%.
How much will be the listing gain in Emcure Pharma IPO?
Emcure Pharma IPO will get listing gain of 28.77%. (Approx.)
